Published in Dermatoendocrinol on March 01, 2009
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
New perspectives on antiacne plant drugs: contribution to modern therapeutics. Biomed Res Int (2014) 0.80
The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med (1995) 6.17
The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science (2004) 3.20
Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev (2000) 2.98
Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J (2005) 2.23
Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol (2005) 1.76
Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J (2001) 1.74
Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol (2006) 1.72
Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol (2005) 1.54
Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci (2004) 1.50
Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology (2003) 1.46
The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci (2006) 1.43
What is the pathogenesis of acne? Exp Dermatol (2005) 1.40
Production and release of proopiomelanocortin (POMC) derived peptides by human melanocytes and keratinocytes in culture: regulation by ultraviolet B. Biochim Biophys Acta (1996) 1.39
CRH functions as a growth factor/cytokine in the skin. J Cell Physiol (2006) 1.38
Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol (2004) 1.37
Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun (1995) 1.37
Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci U S A (2002) 1.22
Acne: inflammation. Clin Dermatol (2004) 1.20
Potential mechanism of skin response to stress. Int J Dermatol (1996) 1.13
CRH and the immune system. J Neuroimmunol (1997) 1.10
Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab (1998) 1.06
Psychologic aspects of acne. Pediatr Dermatol (1991) 1.01
Neuroendocrine regulation of sebocytes -- a pathogenetic link between stress and acne. Exp Dermatol (2004) 1.01
The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease. Exp Dermatol (2006) 1.01
Modulation of integrins and filaggrin expression by Propionibacterium acnes extracts on keratinocytes. Arch Dermatol Res (2007) 0.99
Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol (2008) 0.96
CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes. J Invest Dermatol (2006) 0.94
Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res (1997) 0.92
In vitro modulation of keratinocyte wound healing integrins by zinc, copper and manganese. Br J Dermatol (1999) 0.90
Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes. Br J Dermatol (2005) 0.90
Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol (2005) 0.90
Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol (2007) 0.90
Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology (2001) 0.86
Proopiomelanocortin signaling system is operating in mast cells. J Invest Dermatol (2006) 0.82
Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol (2005) 0.81
Zinc, copper and manganese enhanced keratinocyte migration through a functional modulation of keratinocyte integrins. Exp Dermatol (2000) 0.81
Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications. Front Biosci (2007) 0.80
Acne treatment with topical erythromycin and zinc: effect of Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol (1984) 0.78
Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol (1992) 0.78
Exploration of retinoid activity and the role of inflammation in acne: issues affecting future directions for acne therapy. J Eur Acad Dermatol Venereol (2001) 0.77
Stress, acne and skin surface free fatty acids. Psychosom Med (1970) 0.77
Protective effect of zinc on keratinocyte activation markers induced by interferon or nickel. Acta Derm Venereol (1995) 0.76
Comparative study of the in vitro inflammatory activity of three nickel salts on keratinocytes. Acta Derm Venereol (1998) 0.76
Cations inhibit specifically type I 5 alpha-reductase found in human skin. J Invest Dermatol (1995) 0.76
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet (2002) 2.29
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol (2009) 2.28
Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc Natl Acad Sci U S A (2006) 2.19
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology (2007) 1.41
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One (2012) 1.23
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell (2011) 1.22
An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat (2009) 1.20
Effects of extracellular calcium on the growth-differentiation switch in immortalized keratinocyte HaCaT cells compared with normal human keratinocytes. Exp Dermatol (2008) 1.19
RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J Biol Chem (2005) 1.16
Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. J Invest Dermatol (2005) 1.15
Repair of the three main types of bipyrimidine DNA photoproducts in human keratinocytes exposed to UVB and UVA radiations. DNA Repair (Amst) (2005) 1.14
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol (2005) 1.13
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2002) 1.12
Living with acne. A study of adolescents' personal experiences. Dermatology (2007) 1.07
Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol (2003) 1.05
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother (2002) 1.00
Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote TH2 cell polarization. J Allergy Clin Immunol (2006) 1.00
Peptidylarginine deiminase isoforms are differentially expressed in the anagen hair follicles and other human skin appendages. J Invest Dermatol (2005) 0.97
Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol (2011) 0.97
TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma. Cell Calcium (2007) 0.95
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2007) 0.95
n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta (2007) 0.95
Long-range enhancer associated with chromatin looping allows AP-1 regulation of the peptidylarginine deiminase 3 gene in differentiated keratinocyte. PLoS One (2008) 0.94
Infantile acne: a retrospective study of 16 cases. Pediatr Dermatol (2008) 0.94
Larger yield of cyclobutane dimers than 8-oxo-7,8-dihydroguanine in the DNA of UVA-irradiated human skin cells. Mutat Res (2004) 0.94
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother (2006) 0.94
Deimination is regulated at multiple levels including auto-deimination of peptidylarginine deiminases. Cell Mol Life Sci (2010) 0.93
Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants. Acta Derm Venereol (2010) 0.93
Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol (2011) 0.92
In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol (2007) 0.92
ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma. Pigment Cell Melanoma Res (2009) 0.91
Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol (2007) 0.90
Epidermal growth factor receptor pathway mitigates UVA-induced G2/M arrest in keratinocyte cells. J Invest Dermatol (2007) 0.89
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother (2008) 0.89
Combined 0.1% retinaldehyde/ 6% glycolic acid cream in prophylaxis and treatment of acne scarring. Dermatology (2007) 0.88
Mutation spectrum of human SLC39A4 in a panel of patients with acrodermatitis enteropathica. Hum Mutat (2003) 0.88
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Eur J Immunol (2010) 0.88
Acne counseling to improve adherence. Cutis (2008) 0.88
UVA induces granzyme B in human keratinocytes through MIF: implication in extracellular matrix remodeling. J Biol Chem (2007) 0.88
Avena Rhealba inhibits A23187-stimulated arachidonic acid mobilization, eicosanoid release, and cPLA2 expression in human keratinocytes: potential in cutaneous inflammatory disorders. Biol Pharm Bull (2005) 0.88
Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Exp Dermatol (2011) 0.87
Treatment of a multicentric Merkel cell carcinoma using imatinib. Eur J Dermatol (2012) 0.87
Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One (2011) 0.86
Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. Implication of granzyme B and perforin. J Biol Chem (2006) 0.86
Unrepaired cyclobutane pyrimidine dimers do not prevent proliferation of UV-B-irradiated cultured human fibroblasts. Photochem Photobiol (2004) 0.86
Different strains of Propionibacterium acnes modulate differently the cutaneous innate immunity. Exp Dermatol (2013) 0.85
Dermal condensation formation in the chick embryo: requirement for integrin engagement and subsequent stabilization by a possible notch/integrin interaction. Dev Dyn (2007) 0.85
Differential repair of UVB-induced cyclobutane pyrimidine dimers in cultured human skin cells and whole human skin. DNA Repair (Amst) (2008) 0.84
In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol (2004) 0.84
Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol (2004) 0.84
Epidermal growth factor receptor/beta-catenin/T-cell factor 4/matrix metalloproteinase 1: a new pathway for regulating keratinocyte invasiveness after UVA irradiation. Cancer Res (2009) 0.84
Age-related differences in sensitivity of peripheral blood monocytes to lipopolysaccharide and Staphylococcus aureus toxin B in atopic dermatitis. J Invest Dermatol (2007) 0.84
TLR expression in human melanoma cells. Eur J Dermatol (2012) 0.84
Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol (2007) 0.84
Development of an individual score for melanoma risk. Eur J Cancer Prev (2011) 0.83
Melanoma incidence and patient compliance in a targeted melanoma screening intervention. One-year follow-up in a large French cohort of high-risk patients. Eur J Gen Pract (2014) 0.83
Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res (2008) 0.83
Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother (2015) 0.83
Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy. PLoS One (2013) 0.83
Long-range enhancer differentially regulated by c-Jun and JunD controls peptidylarginine deiminase-3 gene in keratinocytes. J Mol Biol (2008) 0.82
About the cutaneous targets of bexarotene in CTCL patients. Exp Dermatol (2010) 0.82
MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One (2012) 0.82
Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One (2010) 0.82
Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother (2014) 0.82
Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. Eur J Cancer Prev (2012) 0.81
Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells. J Pathol (2009) 0.81
Prospective trial on a school-based skin cancer prevention project. Eur J Cancer Prev (2009) 0.80
Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy. J Transl Med (2011) 0.80
An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context. Cancer Immunol Immunother (2010) 0.80
[Specificity of acne in women older than 25 years]. Presse Med (2008) 0.80